acteremia is associated with adverse outcomes, including serious complications and increased mortality, in patients with febrile neutropenia (FN). [1] [2] [3] Terefore, early recognition of these cases is important because inappropriate initial therapy is related to an increase in overall mortality. 4, 5 According to current evidence-based guidelines, oral ambulatory treatment is an alternative in low-risk patients. 6 Te detection of bacteremia is relatively infrequent in this scenario, because the pretest probability and blood culture yield are expected to decrease. 7 Tus, bacteremia is reported in 10%-30% of FN episodes, 8 with a lower prevalence (7%-10%) in low-risk groups. 9, 10 Nonetheless, the detection of micro-organisms usually requires 24-48 hours, 11 resulting in some patients being discharged from hospital, which can lead to a cause of treatment failure. 12 On laboratory determination of bacteremia, reassessment of the clinical condition, microbial sensitivity, and treatment adherence are necessary, 13 with a proportion of these patients requiring intravenous therapy. 14, 15 Te MASCC (Multinational Association for Supportive Care in Cancer) index is the most widely accepted model to identify low-risk episodes of FN that can be safely treated at home. 16 Nonetheless, it remains under debate whether bacteremic patients with predicted low-risk episodes could beneft from hospital admission and aggressive intravenous antibiotic therapy while they wait for the blood culture results. 17, 18 Hence, it would be of great clinical interest to identify low-risk FN patients who present with bacteremia so that outcomes can be optimized.
We have performed a nested case-control study to determine the prognostic impact of bacteremia in this population. A secondary objective was to analyze the risk factors for bacteremia in clinically stable outpatients.
Methods

Patients
We reviewed the medical records of all adult (≥ 18 years) outpatients who were admitted to an oncology ward in a tertiary-care hospital during 1998-2006 with a diagnosis of FN within the setting of a solid neoplasm. FN was defned as fever ≥ 38 °C for over 1 h, with neutropenia ≤ 500 cells/mm −3 (or ≤ 1,000 cells/mm −3 but with a predicted decrease to ≤ 500 cells/mm −3 ). Episodes of FN were excluded if the work-up and antibiotic therapy did not comply with contemporary Infectious Diseases Society of America guidelines. 19 Te study was approved by the institution's local ethics committee.
Study design
Patients were classifed into 2 main categories: clearly unstable patients (CUPs) and apparently stable patients (ASPs), as previously defned by our group. 20 CUPs were defned as cases with acute septic shock, hypotension, acute organ failure, and/or extensive infection (meningitis, pneumonia, typhlitis, cholangitis, pyelonephritis, or cellulitis > 5 cm in diameter and were excluded from analysis because they represented well-known and easily recognizable high-risk situations. Patients diagnosed with FN but with none of the aforementioned criteria were considered to be ASPs and were included in the study. During the initial work-up, 2 sets of blood cultures were obtained before antimicrobial therapy, with samples drawn through each lumen of a central venous catheter, if present, or from 2 diferent peripheral vein sites.
Outcomes and predictive factors for bacteremia
Te main outcome measure was the incidence of clinically signifcant bacteremia in ASPs with FN. All of these cases fulflled the defnition of clinically signifcant bacteremia in accordance with the US Centers for Disease Control and Prevention's National Healthcare Safety Network (CDC-NHSN) criteria. 21 Terefore, isolation of coagulase-negative staphylococci (CoNS) was considered as contamination unless 2 blood samples were positive or in cases of central-line-associated infections.
Other endpoints were: failure of antimicrobial therapy, time of hospitalization, intended duration of the antibiotic treatment, time to defervescence, and serious complications as defned by Klastersky and colleagues 7 . Te medical records of the ASP group were analyzed to estimate the incidence of bacteremia and complications. To assess the risk factors for bacteremia in the ASPs, we designed a nested case-control study. Cases were defned as outpatients with clinically relevant bacteremia (n = 42). Patients without bacteremia were randomly assigned to the control group with a ratio of 1:4 for cases and controls, respectively, and an additional 25% of controls to compensate for missing values (n = 265). On the basis of a review of the literature, we selected the potential predictors for bacteremia. We omitted variables that were not available in the emergency department setting. Time to blood culture positivity was calculated from the time of admission. For continuous variables, cut-ofs were defned according to common use and US National Cancer Institute's toxicity scale criteria. A MASCC score of < 21 was used to defne high risk. Clinical stage M1 (TNM IV) and unresected, locally advanced (TNM III) cancer associated with anatomic distortions were defned as advanced cancer.
Statistical considerations
Standard statistics were used to describe our sample. For univariate analysis, we used the chi-squared and Fisher exact tests to identify the potential risk factors for bacteremia. Te Mann-Whitney test was used to compare means. A combination of host features representing chronic vulnerability and acute traits related to microbial virulence were considered ( Table 1 ). All of the tests were two-sided, and P values of < .05 were considered signifcant.
We calculated the sensitivity and specifcity of the MASCC (Multinational Association for Supportive Care in Cancer) index to predict both complications and bacteremia. We relied on the area under receiver operating characteristic (ROC) curve to assess the discrimination ability of the MASCC score in this population. To address the problem of integrating bacteremic status and the MASCC score, several models were constructed by means of subtracting points from the MASCC score in bacteremic episodes, with the fnal combined model being selected as the highest area under the ROC curve.
Univariate and multivariate logistic regression analyses were performed to determine the risk factors for bacteremia. Variables with P values of < .10 were eligible for multivariate analysis. Potential overlapping or redundancy was a criterion for exclusion. A bootstrap procedure was used to test the model ft and derive biascorrected confdence intervals. Te statistical analyses were carried out with the SPSS 21 software (SPSS Inc, Chicago, IL, USA).
Results
Patients and febrile neutropenic episodes
We reviewed the medical records of 861 episodes of FN. Of those, 692 episodes in 631 patients were classifed as ASPs (80%), and 169 (20%) as CUPs ( Figure 1 ). Te baseline characteristics of the ASP group and the main features of the FN episodes are shown in Table 1 . Notably, the rates of bacteremia (6%, n = 42), serious complications (7.3%, n = 51), and inpatient mortality (1.3%, n = 9) were lower than the average rates reported in other studies. Te most frequent microorganisms isolated in the 42 episodes with bacteremia were Escherichia coli (30%, n = 13), followed by Pseudomonas aeruginosa (21%, n = 9), CoNS (9%, n = 4), Staphylococcus aureus (9%, n = 4), and Streptococcus spp. (7%, n = 3; Table 2 ). In addition, 2 CoNS were not considered as true bacteremias but as potential contaminants. Te time to blood culture positivity was less than 24 hours in 16% of the 42 episodes with bacteremia, 24-48 hours in 21%, and 48-72 hours or longer in the remaining patients.
Of the total set of blood cultures, 64% (n = 27) were due to Gram-negative bacteria. Among cases with bacteremia, the most common diagnoses were fever without a focus of infection in 61% (n = 26), moderate infections (urinary and chronic bronchitis) in 21% (n = 9), mild infections (cellulitis, odontogenic infection, mild enteritis, and upper respiratory infections) in 19% (n = 8) and catheter-related infection in 2% (n = 1).
Outcomes associated with positive blood cultures
Patients with bacteremia presented with more complications than did the nonbacteremic controls (33% vs 5.6%; odds ratio [OR], 8.2; P < .0001), mainly hypotension and acute respiratory failure. Compared with the controls, patients with bacteremia presented with the following:
A nearly 4-fold more frequent fever lasting more than 24 hours (59% vs 13%, P < .0001); n A longer mean time to defervescence (3.8 vs 2.1 days, P = .008); Staphylococcus aureus 4 (9) Streptococcus spp.
(7)
Enterococcus faecalis 2 (5)
Pseudomonas fuorescens 1 (2)
Enterobacter cloacae 1 (2)
Staphylococcus haemolyticus 1 (2)
Bacteroides uniformis 1 (2) Bacillus spp.
(2)
Salmonella typhi 1 (2)
Klebsiella oxytoca 1 (2) a Percentages do not total 100 because of the rounding.
More frequent treatment failure (43.9% vs 8.4%, P = < .001), persisting even on restricting the analysis to either failures due to clinical progression or microbiological criteria (18.6% vs 5%, P = .01); n A longer hospital stay (9.9 vs 6.4 days, P = .001);
n Development of delayed lung infltrates (9.5% vs 2.7%; OR, 3.6; P = .03); and n Higher overall mortality (7.1% vs 0.9%; OR, 8.2; P = .01).
On analysis of the prognostic role of other concurrent sites of infection alongside with bacteremia, bacteremic lower respiratory tract infection was the only diagnosis associated with adverse outcomes (60% vs 25%, P = .05).
Role of the MASCC index for predicting complications in patients with bacteremia
We observed a signifcant trend to low-risk episodes (MASCC, ≥ 21) in nonbacteremic patients compared with those with bacteremia (90% vs 76.2%, respectively; P = .01). Te ROC curves obtained on application of the MASCC score, with or without bacteremic status, to the ASP cohort did not signifcantly difer ( Figure  2 ). Te MASCC score was found to detect unexpected complications in the whole ASP group, with the follow- As a result of the previous selection of stable patients, no case of hypotension, previous inpatient status or acute leukemia was included, thereby defning a very diferent sample set from that in which the MASCC score was developed (Table 3) . Terefore, on considering only bacteremic patients, the MASCC score was useful, albeit limited to chronic obstructive pulmonary disease (COPD; OR, 4.6) and dehydration (OR, 5), with no statistically signifcant diferences in the remaining covariates. Severe complications were lower in bacteremic patients with predicted low-risk (MASCC, ≥ 21) episodes (25% vs 60%; OR, 4.5; P = .04). Te sensitivity and specifcity of the MASCC score to predict severe complications among bacteremic patients were 43% and 86%, respectively.
Predictors of bacteremia in apparently stable patients
Univariate analysis was performed to evaluate the risk factors for bacteremia (Table 4) . On multivariate analysis (Table 5 
Discussion
In recent years, randomized clinical trials have demonstrated that outpatient management for low-risk FN is both feasible and safe, with selection criteria generally involving the absence of shock, acute organ dysfunction, or specifc infections. 22 Te MASCC score is the most validated risk prediction tool to select low-risk patients, but the optimal method for making acceptable risk decisions remains uncertain, 23 since serious complications occur in 9%-15% of predicted low-risk episodes despite the application of this index. 7, 24 Terefore, it is of great interest among clinicians to identify causes of prognostic uncertainty in order to reduce the rate of misclassifcation and optimize individualized management.
Documented bacteremia has been reported to be around 10% in neutropenic patients with solid tumors. 8, 25, 26 Several studies have reported higher attributable mortality rates in neutropenic patients with bacteremia, 4, 5 and this should be taken into account in patients who are discharged home. Unfortunately, careful clinical assessment does not necessarily prevent the discharge of some patients with unsuspected bloodstream infections. Although some of these cases might respond well to oral treatment, several studies on outpatient management have shown bacteremia to be a cause of hospital readmission and severe complications. 27, 28 Microbial sensitivity to oral antibiotics is another major concern in bacteremic patients. For example, during the study period, only 38% of the E coli isolates were sensitive to ciprofoxacin.
Terefore, it remains an area of interest for physicians to determine the causes and risk factors of bacteremia in otherwise low-risk episodes. We have found that a simple defnition of clinical stability, based on the exclusion of the most severe infections, 20 is associated with a low rate of bacteremia (6% of episodes). Nevertheless, bacteremic status showed substantial efects on patient prognosis, yielding a high rate of complications (33%, 14 of 42 episodes) and infection-associated mortality (7%, 3 of 42 episodes), thereby defning this group as a high-risk population. Moreover, bacteremia was also associated with other adverse outcomes such as longer hospital stay and treatment failure.
Peripheral blood cultures taken in the emergency department are not available at the time of initial assessment. Because failure to suspect possible bacteremia may lead to undertreatment in some cases, it is also important to determine whether bacteremia may be predicted in clinically stable neutropenic outpatients. Previous reports have shown that bacteremia is particularly diffcult to predict in this setting, with a low positive predictive value in a validation set for a prediction model. 29 We have identifed 4 risk factors to aid in the prediction of bacteremia in ASPs: temperature ≥ 39⁰C/102.2⁰F, rigors, ECOG PS of ≥ 2, and advanced cancer. Although these variables should be confrmed in further validation studies, they may be of use in neutropenic bacteremia. High-grade fever has previously been associated with bacteremia in low-risk FN episodes, 26 with the rate of bacteremia generally being correlated with the magnitude of fever. [29] [30] [31] Rigors have also been related to bacteremia in both neutropenic, 32,33 and non-neutropenic patients. 34 Te performance status has been proposed as a prognostic factor in low-risk FN, 24 and both immunosuppression and the anatomical distortion associated with advanced cancer are risk factors predisposing serious infections.
With respect to the performance of the MASCC score, Paesmans and colleagues have reported that the integration of the bacteremic status did not increase the accuracy of the MASCC model to identify patients at low-risk of life-threatening complications. 8 One way to interpret that observation is that the MASCC score is efective in identifying low-risk bacteremic episodes. Tis efectiveness has also been attributed to the Talcott classifcation. 25 However, none of these previous series were stratifed according to the clinical presentation, thus, the prognostic role in specifc populations, such as clinically stable patients, remains uncertain. Although the addition of bacteremic status to the MASCC score did not improve its discriminatory ability, one of the elements of concern that arise from our data is that 68% of bacteremic patients had a MASCC score of ≥ 21, whereas 57% of the complications occurred among predicted low-risk episodes (Table 3) .
Beyond the necessity for further confrmation, the potential implications in clinical practice or possible future directions for research that could emerge from these data are conditioned by the fact that all patients from this cohort were managed as inpatients. As a result, it is unlikely that our conclusions could be used to select cases for hospital discharge but actually to identify those apparently healthier patients who should never be sent home because they are at risk of developing serious infections. Conversely, given the low probability (2%) of bac- teremia in patients who are afebrile with a provisional sterile culture after 48 hours, a strategy of early rather than immediate discharge could be recommended as long as the bacteremic status remains of concern in specifc patients, despite being determined to be clinically stable at frst presentation. With respect to the criteria for discrimination between true bacteremia and contamination, all cases fulflled the CDC-NHSN defnition of clinically signifcant bloodstream infection. 21 Terefore, we excluded 2 cases in which CoNS was isolated in only 1 blood sample. However, 4 other isolates of CoNS were identifed as potentially true bacteremias, with central-line infection in 3 patients and cellulitis in the fourth. Tese results are in accordance with García-Vázquez and colleagues, who have recently analyzed this issue and found that cancer, chemotherapy, neutropenic sepsis and previous immunosuppression are associated with clinically signifcant bacteremia by CoNS. 35 Isolations of Staphylococcus hominis and Bacteroides uniformis were also identifed as true bacteremias, because patients had a signifcant cutaneous barrier disruption and advanced colorectal cancer, respectively.
In conclusion, bacteremia is a potential source of prognostic uncertainty in patients with FN otherwise considered clinically stable. Although accurate prediction will continue to be difcult in the future, clinical suspicion of bloodstream infections can be useful in neutropenic patients to determine the optimal time of hospital discharge.
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